Navigation Links
Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
Date:8/26/2008

JERUSALEM and NEEDHAM, Massachusetts, August 26 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. (SWX: ORIDN) today announced an OEM agreement with Spacelabs Healthcare, a leading global medical device and service company. With this agreement, Spacelabs now employs Oridion Microstream(R) capnography technology in its new, compact and ultra-lightweight patient monitoring system, elance.

Spacelabs Healthcare, recognizing the importance of monitoring CO2, has decided to use the Oridion patented Microstream capnography technology and proprietary EtCO2 sampling technology in its new elance patient monitoring system. Microstream capnography technology and FilterLine(R) breath sampling products improve patient safety by providing the earliest assessment of a patient's ventilatory status. The Spacelabs new elance monitor with Microstream technology is being launched in the current quarter.

Gerry Feldman, President of Oridion Systems Ltd. said: "We are very proud to have entered into this agreement with Spacelabs Healthcare. It demonstrates our ability to further broaden our already existing, strong portfolio of leading global OEM partners. As our partner, Spacelabs will support the Oridion mission to increase patient safety and improve patient outcomes by employing our world-class Microstream CO2 measurement solutions within their systems."

"Spacelabs is very excited to have the advanced Microstream CO2 measurement technology from Oridion integrated into our new patient monitoring system," said Nicholas Ong, Group President, Emerging Markets Organization at Spacelabs Healthcare, Inc.

About Oridion

Oridion Systems Ltd. (http://www.oridion.com ) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

About Spacelabs Healthcare

Spacelabs Healthcare is a wholly owned subsidiary of OSI Systems, Inc. (Nasdaq: OSIS). Spacelabs Healthcare, Inc. is an international developer, manufacturer and distributor of medical equipment and services including solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories selling to hospitals, clinics and physician offices. Additionally, the company provides centralized cardiac safety and diagnostic services (QT Studies, ECG, Holter, ABP, and Event Monitoring) to biopharmaceutical companies undertaking clinical trials. Spacelabs Healthcare, Inc. employs approx. 1,100 personnel in its offices located in the United States, UK, Canada, France, Germany, Finland, India and Singapore. For more information, visit http://www.spacelabshealthcare.com.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.

For further Oridion information please contact:

Alan Adler, Chairman and Chief Executive Officer

Walter Tabachnik, Chief Financial Officer

Elena Gerberg, Investor Relations

e-mail: investor@oridion.com

website: http://www.oridion.com

phone: +972-2-589-9159

address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

For further Spacelabs information please contact

Dan Prueher

e-mail: dan.prueher@spacelabs.com

website: http://www.spacelabshealthcare.com

phone : +1-608-695-5957


'/>"/>
SOURCE Oridion Systems Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributors Association
2. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
3. Hoya Vision Care Expands in Czech Republic
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. GenVault Expands Scientific Advisory Board
6. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
7. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
8. Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office
9. SAFC Supply Solutions Expands Halal Offer in Flavors & Fragrances Product Line
10. PAREXEL Expands Global Clinical Logistics Capabilities
11. BioXcel Expands Its Capability in Business Analytics Support Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... 2016 Strasbourg, France , ... --> Strasbourg, France , to the US ... is pleased to announce that it acted as an advisor ... in Strasbourg, France , to the US ... --> Transgene (Euronext: TNG), a member of ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):